Enzo Biochem (ENZ) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Enzo Biochem Reports Fiscal Second Quarter Results
March 12, 2015 4:15 PM EDTNEW YORK--(BUSINESS WIRE)-- Enzo Biochem Inc. (NYSE: ENZ) today reported results for the fiscal second quarter ended January 31, 2015.
Year over year revenues for the quarter and first half both increased, despite persisting unusually adverse winter conditions which adversely affected the Clinical Lab. Clinical Lab revenue increased 6% for the second quarter compared to the year earlier period. Foreign currency movements impacted Life Sciences results, which otherwise would have been unchanged for the second compared to the year earlier period. Consolidated... More